Please use this identifier to cite or link to this item:
Title: Empagliflozin in combination with oral agents in young and overweight/obese Type 2 diabetes mellitus patients: a pooled analysis of three randomized trials
Authors: Romera, Irene
Gomis, Ramon
Crowe, Susanne
De Pablos Velasco, Pedro Luis 
Aranda, Unai
García, Arantxa
Kis, Sanja Giljanovic
Naderali, Ebranhim
UNESCO Clasification: 320502 Endocrinología
Keywords: Glycemic control
Oral agents
Therapy, et al
Issue Date: 2016
Journal: Journal of Diabetes and its Complications 
Abstract: Aims This analysis aimed to evaluate efficacy and safety of empagliflozin in combination therapy in < 65 y.o. patients, overweight/obese, and with uncontrolled T2DM. Methods Pooled analysis from three phase-III trials, in < 65 y.o. patients, with BMI 25–35 kg/m2, and HbA1c ≥ 8% at baseline. Patients (N = 439) were randomized to placebo (n = 138), empagliflozin 10 mg (n = 160), or empagliflozin 25 mg (n = 141) once daily (24 weeks) as add-on to metformin, to metformin plus sulfonylurea, or to pioglitazone ± metformin. Results At week 24, adjusted mean (SE) changes from baseline in HbA1c were − 0.19% (0.07) for placebo vs. − 1.10% (0.07) and − 1.10% (0.07) for empagliflozin 10 and 25 mg, respectively (both p < 0.001). Adjusted mean (SE) changes from baseline in weight were − 0.33 kg (0.21) for placebo vs. -1.94 kg (0.19) and − 2.14 kg (0.20) for empagliflozin 10 and 25 mg, respectively (both p < 0.001). Adverse events were reported in 57.2% on placebo, 64.4% on empagliflozin 10 mg and 59.6% on empagliflozin 25 mg. Genital infection AEs were reported in 1.4% on placebo, 3.8% on empagliflozin 10 mg, and 5.0% on empagliflozin 25 mg. Conclusions In this specific population, empagliflozin in combination with other oral agents, significantly reduced HbA1c and body weight and was well tolerated.
ISSN: 1056-8727
DOI: 10.1016/j.jdiacomp.2016.07.016
Source: Journal of Diabetes and its Complications [ISSN 1056-8727], v. 30 (8), p. 1571-1576
Appears in Collections:Artículos
Show full item record


checked on Dec 3, 2023


checked on Dec 3, 2023

Page view(s)

checked on Oct 14, 2023

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.